株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

先進薬物送達システムの世界市場と技術:エンドユーザーを中心に

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users

発行 BCC Research 商品コード 292905
出版日 ページ情報 英文 153 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
先進薬物送達システムの世界市場と技術:エンドユーザーを中心に Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users
出版日: 2014年01月06日 ページ情報: 英文 153 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

医薬品業界の今後の成長において、薬物送達システムは非常に重要な側面の1つとなっています。多様な薬物送達システムの分野における幅広い研究の結果、医薬品の体内への輸送を円滑化するとともに、期待される治療効果を安全に達成するという、その特殊な機能性が明らかとなりました。各産業はこれらの薬物送達システムの利点を、自社の生産・プロセスに反映するための研究に着手しています。世界の先進薬物送達システム売上高は2013年には1,819億米ドルになるものと推定されており、その後CAGR(年間複合成長率)3.2%で市場は拡大し、2018年には市場規模は2,128億米ドルの規模に達することが見込まれています。

当レポートでは、世界の先進薬物送達システム市場を取り上げ、多様な薬物送達手法を概括し、タイプ別・地域別・エンドユーザー別に市場を分析するとともに、特に疾患別にエンドユーザー別市場を詳細に分析し、加えて特許分析、企業プロファイルをまとめるなど、概略下記の構成でお届けいたします。

第1章 イントロダクション:はじめに

  • 調査の目的
  • 調査実施理由
  • 対象読者
  • 調査範囲
  • 調査手法
  • 情報源
  • 著者について
  • 関連レポート
  • BCCオンラインサービス
  • 免責

第2章 サマリー

第3章 概要

  • 投薬形態の必要性
  • 技術による薬物送達の分類
    • 持続放出薬物送達
    • プロドラッグ
    • インプラントおよび子宮内避妊器具(IUD)
    • 標的薬物送達
  • ポリマー薬物送達
  • 投薬方法による薬物送達の分類
    • 経口薬物送達
    • 注射または非経口薬物送達
    • 肺薬物送達
    • 経鼻薬物送達
    • 経口粘膜薬物送達
    • 直腸薬物送達
    • 眼球薬物送達
    • 経皮薬物送達

第4章 規制側面

  • 2009-2013年に認可された新製品
  • FDAのリコールおよび安全警報

第5章 新たな動き

  • 新規パートナーシップ、合併および買収
  • 新製品
  • パイプライン製品

第6章 世界市場

  • タイプ別市場
    • 市場概要
    • 市場売上
    • 市場シェア
  • 地域別市場
    • 持続放出薬物送達システム
    • プロドラッグ
    • インプラント・IUD
    • 経粘膜薬物送達システム
    • 標的薬物送達
    • 経皮薬物送達
    • ポリマー薬物送達
  • エンドユーザー別市場
    • 市場概要
    • 市場売上
    • 市場シェア

第7章 エンドユーザー別市場

  • 心疾患
  • 腫瘍
  • 消化器系
  • 泌尿器
  • 糖尿病
  • 中枢神経系
  • 呼吸器薬物送達システム
  • 炎症性疾患およびアレルギー
  • 眼科
  • ウィルス性・細菌性疾患
  • ホルモン補充療法および婦人科
  • その他

第8章 特許分析

  • 年別特許
  • 分類別特許
  • タイプ別特許
  • 企業別特許
  • 国別特許
  • 出願者別特許

第9章 現況

第10章 企業プロファイル

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • アステラス製薬
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • IOSANTE PHARMACEUTICALS, INC.
  • OEHRINGER INGELHEIM
  • OSTON SCIENTIFIC
  • RISTOL MYERS SQUIBB
  • ELGENE CORPORATION
  • EPHALON, INC.
  • OLUMBIA LABORATORIES, INC.
  • エーザイ
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • 久光製薬
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

第11章 付属資料I

図表

目次
Product Code: PHM166A

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.

This report provides:

  • An overview of the global market for drug delivery systems, with a focus on the end users.
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Discussion of the current state, setbacks, innovations, and the future needs of the market.
  • Analyses of the regulatory environment and the technology involved, including the latest developments.

STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.

This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.

A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.

Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.

R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • NEED FOR THE DOSAGE FORMS
    • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
  • CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY
    • SUSTAINED RELEASE DRUG DELIVERY
      • Oral Sustained Release Drug Delivery
      • Intramuscular (IM) Injections or Microsyringes
        • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
    • PRODRUGS
      • Subtypes of Prodrugs
        • TABLE 3: CLASSIFICATION OF PRODRUGS
      • Need for Prodrugs
        • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
    • IMPLANTS AND INTRAUTERINE DEVICES (IUDS)
      • Copper-based Devices
      • Hormonal-based Devices
      • Mechanism
        • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
    • TARGETED DRUG DELIVERY
      • Delivery Vehicles
        • Liposomes
          • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
        • Micelles and Dendrimers
          • Mechanisms of Drug Delivery
          • Advantages of Dendrimers
        • Biodegradable Particles
        • Artificial DNA Nanostructures
        • Monoclonal Antibodies
      • Applications
        • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
  • POLYMERIC DRUG DELIVERY
    • Applications of Polymers in Drug Delivery
      • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
    • Pegylation
      • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
    • Future Perspectives
  • CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION
    • ORAL DRUG DELIVERY
      • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • INJECTABLE OR PARENTERAL DRUG DELIVERY
      • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
    • PULMONARY DRUG DELIVERY
      • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • NASAL DRUG DELIVERY
      • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • ORAL MUCOSAL DRUG DELIVERY
      • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
    • RECTAL DRUG DELIVERY
      • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • OCULAR DRUG DELIVERY
      • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TRANSDERMAL DRUG DELIVERY
      • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY

CHAPTER 4 - REGULATORY ASPECTS

  • NEW PRODUCTS APPROVED IN 2009-2013
    • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
  • FDA RECALLS AND SAFETY ALERTS
    • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013

CHAPTER 5 - NEW DEVELOPMENTS

  • NEW PARTNERSHIPS, MERGERS AND ACQUISITION
    • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
  • NEW PRODUCTS
    • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
  • PIPELINE PRODUCTS
    • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET

CHAPTER 6 - GLOBAL MARKETS

  • MARKET BY TYPE
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
      • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
  • MARKET BY REGION
    • SUSTAINED RELEASE DRUG DELIVERY SYSTEM
      • Market Overview
      • Market Revenue
        • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
        • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • PRODRUGS
      • Market Overview
      • Market Revenue
        • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
        • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
    • IMPLANTS AND IUDS
      • Market Overview
      • Market Revenue
        • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
        • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • TRANSMUCOSAL DELIVERY SYSTEMS
      • Market Overview
      • Market Revenue
        • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • TARGETED DRUG DELIVERY
      • Market Overview
      • Market Revenue
        • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • TRANSDERMAL DRUG DELIVERY SYSTEM
      • Market Overview
      • Market Revenue
        • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
        • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • POLYMERIC DRUG DELIVERY
      • Market Overview
      • Market Revenue
        • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
      • Market Share
        • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
        • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
  • MARKET BY END USERS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
      • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)

CHAPTER 7 - MARKET BY END USERS

  • TABLE 42: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
  • FIGURE 19: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
  • CARDIOVASCULAR DISEASES
    • MARKET REVENUE
      • TABLE 43: GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 20: GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 44: MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
      • FIGURE 21: MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • ONCOLOGY
    • MARKET REVENUE
      • TABLE 45: GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 22: GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 46: MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
      • FIGURE 23: MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • GASTROINTESTINAL SYSTEMS
    • MARKET REVENUE
      • TABLE 47: GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 24: GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 48: GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)
      • FIGURE 25: GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)
  • UROLOGY
    • MARKET REVENUE
      • TABLE 49: GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 26: GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 50: MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
      • FIGURE 27: MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • DIABETES
    • MARKET REVENUE
      • TABLE 51: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 28: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 52: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)
      • FIGURE 29: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)
  • CENTRAL NERVOUS SYSTEM
    • MARKET REVENUE
      • TABLE 53: GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 30: GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 54: MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
      • FIGURE 31: MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • RESPIRATORY DRUG DELIVERY SYSTEMS
    • MARKET REVENUE
      • TABLE 55: GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 32: GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 56: MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
      • FIGURE 33: MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
  • INFLAMMATORY DISEASES AND ALLERGIES
    • MARKET REVENUE
      • TABLE 57: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 34: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 58: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)
      • FIGURE 35: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)
  • OPHTHALMOLOGY
    • MARKET REVENUE
      • TABLE 59: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2018 ($ MILLIONS)
      • FIGURE 36: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 60: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)
      • FIGURE 37: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)
  • VIRAL AND BACTERIAL DISEASES
    • MARKET REVENUE
      • TABLE 61: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 38: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 62: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)
      • FIGURE 39: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)
  • HORMONE REPLACEMENT THERAPY AND GYNECOLOGY
    • MARKET REVENUE
      • TABLE 63: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS)
      • FIGURE 40: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 64: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)
      • FIGURE 41: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)
  • OTHERS
    • MARKET REVENUE
      • TABLE 65: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, THROUGH 2018 ($ MILLIONS)
      • FIGURE 42: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2911-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 66: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)
      • FIGURE 43: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)
    • MARKET SHARE OF APPLICATIONS
      • TABLE 67: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)
      • FIGURE 44: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)

CHAPTER 8 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 68: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • FIGURE 45: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
  • PATENTS BY CATEGORY
    • TABLE 69: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • FIGURE 46: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
  • PATENTS BY TYPE
    • TABLE 70: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
  • PATENTS BY COMPANY
    • TABLE 71: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
  • PATENTS BY COUNTRY
    • TABLE 72: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
  • PATENTS BY ASSIGNEE
    • TABLE 73: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
    • FIGURE 47: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

CHAPTER 9 - CURRENT SITUATION

CHAPTER 10 - COMPANY PROFILES

  • 3M COMPANY
  • ABBOTT LABORATORIES
  • ACTAVIS INC.
  • AKELA PHARMA INC.
  • AKORN, INC.
  • ALCON INC.
  • ALEXION PHARMACEUTICALS, INC.
  • ALKERMES
  • ALLERGAN INC.
  • AMGEN INC.
  • A.P. PHARMA
  • APTALIS PHARMA INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • ATON PHARMA
  • BAUSCH & LOMB
  • BAXTER INTERNATIONAL INC.
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC
  • BIOSANTE PHARMACEUTICALS, INC.
  • BOEHRINGER INGELHEIM
  • BOSTON SCIENTIFIC
  • BRISTOL MYERS SQUIBB
  • CELGENE CORPORATION
  • CEPHALON, INC.
  • COLUMBIA LABORATORIES, INC.
  • EISAI CO., LTD
  • ELAN DRUG TECHNOLOGIES
  • ENZON PHARMACEUTICALS
  • GENENTECH INC.
  • GENEREX BIOTECHNOLOGY CORPORATION
  • GENZYME CORPORATION
  • GILEAD SCIENCES, INC.
  • GLAXOSMITHKLINE PLC
  • HISAMITSU PHARMACEUTICAL CO., INC.
  • IMCLONE SYSTEMS INC.
  • JANSSEN BIOTECH, INC.
  • JOHNSON & JOHNSON
  • KEMPHARM, INC.
  • K.V. PHARMACEUTICAL CO.
  • LAVIPHARM CORPORATION
  • MANNKIND CORPORATION
  • MERCK & CO.
  • MYLAN LABORATORIES INC.
  • NEKTAR THERAPEUTICS
  • NEUROGESX INC.
  • NEWGEN BIOPHARMA
  • NOVARTIS AG
  • NOVAVAX, INC.
  • NOVEN PHARMACEUTICALS, INC.
  • NYCOMED US INC.
  • OSI PHARMACEUTICALS, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PDL BIOPHARMA, INC.
  • PFIZER INC.
  • QLT INC.
  • ROCHE HOLDING AG
  • SANOFI SA
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERAJECT, INC.
  • UMEWORLD LTD.
  • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
  • XEL PHARMACEUTICALS, INC.

CHAPTER 11 - APPENDIX I

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: HISTORIC EVENTS IN DRUG DELIVERY
    • TABLE 2: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
    • TABLE 3: CLASSIFICATION OF PRODRUGS
    • TABLE 4: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
    • TABLE 5: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
    • TABLE 6: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
    • TABLE 7: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
    • TABLE 8: ADVANTAGES AND DISADVANTAGES OF POLYMERS
    • TABLE 9: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
    • TABLE 10: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • TABLE 11: ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY
    • TABLE 12: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • TABLE 14: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
    • TABLE 15: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • TABLE 16: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TABLE 17: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
    • TABLE 18: FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013
    • TABLE 19: PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 20: SAFETY ALERTS, 2009 TO JUNE 2013
    • TABLE 21: NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013
    • TABLE 22: NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013
    • TABLE 23: PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET
    • TABLE 24: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
    • TABLE 26: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • TABLE 28: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 29: MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)
    • TABLE 30: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 31: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • TABLE 32: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 34: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 36: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 ($ MILLIONS)
    • TABLE 38: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
    • TABLE 40: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
    • TABLE 42: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 44: MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • TABLE 45: GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 46: MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • TABLE 47: GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)
    • TABLE 49: GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • TABLE 51: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH 2018 ($ MILLIONS)
    • TABLE 52: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)
    • TABLE 53: GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 54: MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • TABLE 55: GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2018 ($ MILLIONS)
    • TABLE 56: MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • TABLE 57: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS)
    • TABLE 58: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)
    • TABLE 59: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2018 ($ MILLIONS)
    • TABLE 60: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)
    • TABLE 61: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS)
    • TABLE 62: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)
    • TABLE 63: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS)
    • TABLE 64: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)
    • TABLE 65: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, THROUGH 2018 ($ MILLIONS)
    • TABLE 66: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)
    • TABLE 67: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)
    • TABLE 68: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • TABLE 69: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • TABLE 70: NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013
    • TABLE 71: NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013
    • TABLE 72: NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013
    • TABLE 73: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 2: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)
    • FIGURE 3: GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 4: MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR 2012 (%)
    • FIGURE 5: GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 6: MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 7: GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 8: MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)
    • FIGURE 9: GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 10: MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 11: GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 12: MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 13: GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 14: MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 15: GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 16: MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)
    • FIGURE 17: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • FIGURE 18: MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)
    • FIGURE 19: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011-2018 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 21: MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 22: GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 23: MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 24: GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 25: GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)
    • FIGURE 26: GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 27: MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 28: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, 2011-2018 ($ MILLIONS)
    • FIGURE 29: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)
    • FIGURE 30: GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 31: MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 32: GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2011-2018 ($ MILLIONS)
    • FIGURE 33: MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)
    • FIGURE 34: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS)
    • FIGURE 35: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)
    • FIGURE 36: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2011-2018 ($ MILLIONS)
    • FIGURE 37: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)
    • FIGURE 38: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, 2011-2018 ($ MILLIONS)
    • FIGURE 39: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)
    • FIGURE 40: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS)
    • FIGURE 41: MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)
    • FIGURE 42: GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2911-2018 ($ MILLIONS)
    • FIGURE 43: MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)
    • FIGURE 44: MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)
    • FIGURE 45: NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013
    • FIGURE 46: NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013
    • FIGURE 47: NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013
Back to Top